SCHEMBL1780077

SCHEMBL1780077

C=CCOC(=O)N1CCNCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
CA2 P00918 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
CHKA P35790 1/20 0.38
CHRNB2 P17787 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRNB3 Q05901 1/20 0.37
CHRNA6 Q15825 1/20 0.37
GPR119 Q8TDV5 1/20 0.36
SLC6A15 Q9H2J7 1/20 0.34
P2RY12 Q9H244 1/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
TPSAB1 Q15661 1/20 0.34
TPSD1 Q9BZJ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20488405 0.98 LMNA (0.42) LMNAMAPK1RAB9ACA2CA12
SCHEMBL30592964 0.93 CA2 (0.42) LMNAMAPK1RAB9ACA2CA12
Trifluoroacetic Acid SCHEMBL18497410 0.89 LMNA (0.45) LMNAMAPK1RAB9ACA2CA12
Morpholine SCHEMBL8023056 0.84 TSHR (0.50) LMNAMAPK1RAB9AGPR119TSHR
SCHEMBL30736650 0.84 CYP1A2 (0.43) LMNAMAPK1RAB9A
SCHEMBL29607392 0.83 CA2 (0.41) CA2CA12CA1CA9CHKA
Hydrochloric Acid SCHEMBL30984509 0.82 CYP1A2 (0.42) LMNAMAPK1RAB9A
SCHEMBL4195614 0.82 LMNA (0.46) LMNAMAPK1RAB9AGPR119SLC6A15
SCHEMBL31505458 0.82 MEN1 (0.53) LMNAMAPK1RAB9ASIGMAR1SMN1; SMN2
Hydrochloric Acid SCHEMBL31249725 0.81 CA2 (0.39) CA2CA12CA1CA9CHKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117631446-B Resist composition and use thereof 湖北鼎龙芯盛科技有限公司 2024-08-06 CN claimed
CN-117631446-A Resist composition and use thereof 张斌 2024-03-01 CN claimed
EP-4039257-B1 PHARMACEUTICAL COMPOSITION AND KIT CONTAINING A PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM BETA-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE FUJIFILM CORP (JP) 2026-05-27 EP disclosed
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORPORATION (JP) 2025-10-23 US disclosed
US-20250162992-A1 METHOD FOR PRODUCING AMIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-05-22 US disclosed
EP-4461724-A1 METHOD FOR PRODUCING AMIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-11-13 EP disclosed
CN-118510751-A Method for producing amide compound 中外制药株式会社 2024-08-16 CN disclosed
CN-117631446-B Resist composition and use thereof 湖北鼎龙芯盛科技有限公司 2024-08-06 CN disclosed
CN-114531850-B Pharmaceutical composition and kit characterized by containing novel penicillin derivative or salt thereof and at least 1 compound selected from beta-lactamase inhibitory compound and antibacterial compound or salt thereof 富士胶片株式会社 2024-08-06 CN disclosed
CN-117631446-A Resist composition and use thereof 张斌 2024-03-01 CN disclosed
EP-4276092-A1 COMPOUND LIBRARY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-15 EP disclosed
US-20170066749-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2017-03-09 US disclosed
WO-2017027684-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. (US) 2017-02-16 WO disclosed
WO-2017027684-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. (US) 2017-02-16 WO disclosed
US-8536181-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC. (US) 2013-09-17 US disclosed
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2011-05-12 US disclosed
US-7569690-B2 Process for producing oxycarbonyl-substituted piperazine derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2009-08-04 US disclosed
US-20060161003-A1 Process for producing oxycarbonyl-substituted piperazine derivative TORAY FINE CHEMICALS CO., LTD. (JP) 2006-07-20 US disclosed
EP-1548010-A1 PROCESS FOR PRODUCING OXYCARBONYL-SUBSTITUTED PIPERAZINE DERIVATIVE Toray Fine Chemicals Co., Ltd. (JP) 2005-06-29 EP disclosed
US-3933802-A New sulphamoylbenzoic acid amides CIBA-GEIGY CORPORATION (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066749-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, FAP, FOLH1 LMNA 3216/4885MAPK1 4438/4885RAB9A 3333/4885
US-20250162992-A1 METHOD FOR PRODUCING AMIDE COMPOUND NAAA, NCAPH, NCAPD2 LMNA 1032/4885MAPK1 4021/4885RAB9A 1680/4885
US-20060161003-A1 Process for producing oxycarbonyl-substituted piperazine derivative DHPS, AQP4, OGFOD1 LMNA 3673/4885MAPK1 3180/4885RAB9A 3720/4885
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION ABCB11, ABCC1, SLC11A2 LMNA 4425/4885MAPK1 383/4885RAB9A 744/4885
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 LMNA 4204/4885MAPK1 2806/4885RAB9A 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.